Ischemic stroke biomarkers in blood

Area of Science:

• Neurology
• Biochemistry
• Clinical Medicine

Background:

• Ischemic stroke is a major cause of adult disability and mortality globally.
• Over 15 million strokes occur annually, highlighting the need for improved risk identification, diagnosis, and prognosis.
• Blood-based biomarkers are being investigated as tools for stroke prediction, diagnosis, and management.

Purpose of the Study:

• To review and summarize blood-based biomarkers for ischemic stroke.
• To categorize biomarkers based on their potential clinical applications in stroke care.
• To highlight the current status and future directions for blood biomarker research in stroke.

Main Methods:

• Literature review of studies on blood biomarkers in ischemic stroke.
• Categorization of identified biomarkers by clinical utility (risk prediction, diagnosis, prognosis, therapy guidance).
• Synthesis of current evidence on the role of various biomolecules (proteins, nucleic acids, lipids) in stroke pathophysiology.

Main Results:

• Numerous blood biomarkers, including proteins, nucleic acids, and lipids, have been identified.
• These biomarkers are related to the underlying pathophysiology of ischemic stroke.
• The clinical utility of these markers spans risk assessment, diagnosis, severity prediction, and treatment guidance.

Conclusions:

• Blood biomarkers hold significant potential for improving the clinical management of ischemic stroke.
• Further research and validation are essential to translate these findings into routine clinical practice.
• The role of blood biomarkers in ischemic stroke is still evolving, requiring continued investigation.